HARBIN, China, March 24 /PRNewswire-Asia/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced preliminary results of a month-long promotion of its potent flu-fighting medicine, Banlangen Granules.
To help increase brand awareness of Banlangen, Renhuang launched the "Anti-Flu Month" campaign in March, the peak of China's flu season, and created specific product training and provided promotional guidance to members of its vast distributor network.
Banlangen Granules are a modern, all-natural formulation of a traditional Chinese medicine and are effective in treating viral cold, sore throat, and tonsillitis without the side effects of harsh chemical medicines. Renhuang introduced the product in September 2009. The Company received significant support from nationwide distributors for its "Anti-Flu Month" campaign activities and has quickly established Banlangen as one of the most popular flu remedies on the Chinese market. As of March 23, Renhuang had received 12,000 purchase orders, more than double the typical monthly demand for the product.
"We're pleased with the results of this promotion, which demonstrated growing market acceptance of our Banlangen Granules," said Mr. Shaoming Li, the Chairman and CEO. "In addition to boosting our sales potential, we are also leveraging our "Anti-Flu Month" campaign to enhance our direct-to-consumer marketing efforts to continue to increase brand awareness and consumer acceptance. We will continue to optimize our promotional and sales efforts to maximize sales while providing the Chinese consumers with the highest quality, all-natural medicinal products."
About Renhuang Pharmaceuticals, Inc.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its extensive distribution network of over 3,000 distributors and more than 70 sales centers across 24 provinces in China.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to continue to effectively promote its products, to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
For more information, please contact:
Company Contact:
Renhuang Pharmaceuticals, Inc.
Ms. Portia Tan, IR Contact
Tel: +86-451-5392-5461
Email: ir@renhuang.com
CCG Investor Relations:
Ms. Lei Huang, Account Manager
Phone: +1-646-833-3417 (New York)
Email: lei.huang@ccgir.com
Web: http://www.ccgirasia.com
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
